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Abstract
Purpose: Antimicrobial, cytotoxicity and clinical performance of a new soft contact lens 
multi-purpose solution (COMPLETE® RevitaLens) based on polyquaternium-1 and alexidine 
dihydrochloride (NuMPS) was evaluated.
Methods: Antimicrobial efÀ cacy was assessed according to ISO 14729 for both biocidal and regimen 
performance against bacteria and fungi. Acanthamoeba efÀ cacy was tested along with ability to 
retain antimicrobial activity on partial evaporation. In vitro cytotoxicity of NuMPS and OPTI-FREE® 
RepleniSH® MPS (MPS-3) was assessed based on ISO 10993-5 and United States Pharmacopeia (USP) 
methods. In addition, a 3 month, double-masked, parallel group clinical trial comparing safety 
and acceptability with respect to MPS-3 was conducted with 4 silicone hydrogel (SiHy) and FDA 
Group IV lens types.
Results: NuMPS showed broad antimicrobial efÀ cacy, including Acanthamoeba, giving a 3-4 log10 
reduction in viability after 6 hours contact time. NuMPS also passed ISO 14729 regimens with SiHy 
and etaÀ lcon lenses for bacteria, fungi and also Acanthamoeba. The cytotoxicity of NuMPS was 
equivalent or better compared to MPS-3. In the clinical trial, there was no statistically signiÀ cant 
between-group difference in corneal staining (p > 0.05). Patients using MPS-3 had more adverse 
events than patients using NuMPS: 11.8 % (11/93) versus 2.8 % (5/177), respectively, (p < 0.05). 
There were no differences noted in cleanliness or wearing comfort (p > 0.05).
Conclusion: Taken together, the results of these studies indicate that the NuMPS is a novel and 
effective soft contact lens care solution.
© 2010 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
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Desarrollo de una nueva solución multiusos para lentes de contacto: 
análisis comparativo de su rendimiento microbiológico, biológico y clínico
Resumen
Objetivos: Se evaluó el rendimiento clínico, antimicrobiano y citotoxicidad de una nueva solución 
multiusos para lentes de contacto blandas (COMPLETE®RevitaLens) basada en policuaternio-1 y 
diclorhidrato de alexidina (NuMPS).
Métodos: Se evaluó la eÀ cacia antimicrobiana en concordancia con ISO 14729, tanto en términos 
de rendimiento biocida como en regimenes de higiene contra bacterias y hongos. Se comprobó la 
eÀ cacia contra Acanthamoeba, así como su habilidad para mantener la actividad antimicrobiana 
ante una evaporización parcial. Se evaluó la citotoxicidad in vitro de NuMPS y de  OPTI-FREE® Re-
pleniSH® MPS (MPS-3). Además, se llevó a cabo un ensayo clínico simultáneo, a doble ciego y de 
3 meses de duración que comparó la seguridad y la aceptabilidad de MPS-3 para 4 lentes de hidro-
gel de silicona (SiHy) y lentes del grupo IV de la FDA.
Resultados: La solución NuMPS mostró una eÀ cacia antimicrobiana amplia, incluso contra Acantha-
moeba, y produjo una reducción logarítmica de 3-4 (log10) en la viabilidad tras 6 horas de contac-
to. Dicha solución también superó ISO 14729 en regímenes con SiHy y lentes etafilcon para 
bacterias, hongos y Acanthamoeba. La citotoxicidad de NuMPS fue equivalente o mejor que la de 
MPS-3. En el ensayo clínico, no se obtuvieron diferencias estadísticamente signiÀ cativas entre los 
grupos en cuanto a tinción corneal (p > 0,05). Los pacientes que utilizaban MPS-3 presentaron más 
fenómenos adversos que los que usaron NuMPS: 11,8 % (11/93) frente a 2,8 % (5/177), respectiva-
mente (p < 0,05). No se observaron diferencias en higiene ni en comodidad durante su uso 
(p > 0,05).
Conclusiones: En su conjunto, los resultados de estos estudios indican que la NuMPS es una nueva 
solución eÀ caz para el cuidado de lentes de contacto blandas.
© 2010 Spanish General Council of Optometry. Publicado por Elsevier España, S.L. Todos los derechos 
reservados.
Introduction
Multi-purpose solutions (MPS) represent the majority of 
systems used for the care of soft contact lenses. 1 They 
comprise a single solution for the rinsing, disinfection 
and storage of lenses and are typically composed of a 
preservative, buffer system and other agents to aid lens 
comfort and cleaning. 2 The ability of these components to 
achieve sufÀ cient antimicrobial efÀ cacy is fundamental to 
safe contact lens use.
Microbial keratitis is a rare but significant risk among 
soft contact lens wearers with a reported incidence of 
4 cases per 10,000 users per year. 3 In keratitis, due to the 
free-living amoebae Acanthamoeba, almost 90 % of cases 
occur in contact lens wearers and the reported incidence 
varies from 1-2 cases per million in the USA or 17-20 in the 
UK. 4 Accordingly, the use of MPS with effective disinfectant 
properties, in conjunction with good compliance to lens care 
hygiene, reduces the incidence of microbial keratitis through 
the prevention or inhibition of potentially pathogenic 
organism growth on the lens surface and within the lens 
storage case. 5-9 The majority of MPS utilize the preservative 
polyhexamethylene biguanide (PHMB) but others use 
the quaternary ammonium compound polyquaternium-1 
(PQ-1) alone or in combination with the amido amine 
myristamidopropyl dimethylamine (MAPD). 2 According to 
international standards, including ISO 14729 and FDA 510(k) 
guidance, contact lens solutions are required to exhibit 
antimicrobial efÀ cacy against select reference strains of 
common bacterial and fungal ocular pathogens. 10,11 However, 
the rigor of such testing has been questioned following 
the association of two MPS with a signiÀ cant rise in cases 
of keratitis due to the À lamentous mould Fusarium and to 
Acanthamoeba. 12-15
The purpose of this review is to evaluate the antimicrobial, 
cytotoxicity and clinical performance of a new MPS (NuMPS: 
COMPLETE® RevitaLens) based on the novel dual disinfection 
combination of PQ-1 and the bis-biguanide alexidine.
Materials and methods
Test organisms and solutions
For the microbiological analysis, the following organisms 
were studied: Pseudomonas aeruginosa (ATCC 9027), 
Serratia marcescens (ATCC 13880), Staphylococcus aureus 
(ATCC 6538), Candida albicans (ATCC 10231), Fusarium 
solani (ATCC 36031) and Acanthamoeba castellanii (ATCC 
50370). Test solutions studied are given in Table 1.
For the bacteria and fungi, stand-alone (biocidal) and 
regimen assays were performed according to ISO 14729. 10 
Briefly, in the stand-alone procedure the test solutions 
were challenged with 1 × 10 6/ml organism and the number 
of survivors determined by culture viability at 0 and 6 hr 
using the WASP Spiral Plater and ProtoCOL colony counter 
system. 16 At each time point the test samples were first 
diluted 1:10 into DifcoW Letheen Broth neutralizing broth 
before determining the number of surviving organisms as 
colony forming units (cfu).
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In the regimen assay, four sets of the following lenses 
were tested per organism: SoÁ ens® 38 (polymacon, Bausch & 
Lomb), Acuvue® 2 (etaÀ lcon A, Vistakon), Acuvue® Advance® 
(galyfilcon, Vistakon), O2Optix®/AirOptix® (lotrafilcon B, 
CIBA Vision), PureVision® (balafilcon A, Bausch & Lomb) 
and BioÀ nity® (comÀ lcon A, CooperVision) lenses. Although 
not required by the protocol, organic soil was included in 
the organism challenge inoculum and comprised a final 
concentration of 300-3000 heat killed Saccharomyces 
cerevisiae (ATCC 9763) in 0.003 % heat-inactivated fetal 
bovine serum. BrieÁ y, four lenses of each test type were 
inoculated with approximately 2 × 10 6 organisms and left to 
adhere for 5 minutes. Each lens was then subjected to a “No 
Rub but Rinse” with NuMPS using 5 seconds rinse per side 
followed by a 6 hour soaking time in 3 ml of the solution 
in a contact lens storage cases (ABS/polypropylene, Abbott 
Medical Optics Inc.). At the end of the regimen procedure, 
each test lens and soaking solution was neutralized in 
DifcoTM Letheen Broth followed by filtration and culture 
of the lens and membrane to determine the presence of 
surviving organisms (cfu).
Acanthamoeba trophozoite and cyst biocidal and regimen 
assays were performed as described previously. 5,17,18 For 
the regimen assay, lenses were inoculated with 4 × 10 4 
trophozoites or cysts per lens and subjected to a “Rub and 
Rinse” regimen with the NuMPS using 4 seconds rub and 
5 seconds rinse per side, followed by a 6 hour soaking time 
in 3 ml of the solution in a contact lens storage cases (ABS/
polypropylene, Abbott Medical Optics Inc.). Remaining 
viable Acanthamoeba on the lenses and in the soak 
solution were determined by culture assay as described 
previously. 5
The capacity  for  the test  so lut ions  to  induce 
Acanthamoeba trophozoite encystment during incubation 
in the solutions was performed according to the method 
described by Kilvington et al. using Complete® MoisturePlus® 
MPS as the positive control solution. This MPS formulation 
has previously been shown to induce signiÀ cant trophozoite 
encystment. 19
Loss of MPS antimicrobial efficacy following partial 
evaporation was also studied. The solutions were evaporated 
under a stream of air to 2× and 4× concentration by weight, 
challenged with F. solani or A. castellanii trophozoites and 
the level of organism kill determined after 6 hr contact 
time.
Cytotoxicity studies
In vitro cytotoxicity potential of NuMPS and MPS-3 
(OPTI-FREE® RepleniSH® Multi-Purpose Solution) was 
evaluated according to USP < 87 > and ISO 10993-5. 11,20,21 
Five soft contact lens types were studied: Soflens® 38 
(polymacon, Bausch & Lomb), Acuvue Advance® (galyÀ lcon 
A, Vistakon), O2Optix® (lotrafilcon B, CIBA Vision), 
PureVision® (balaÀ lcon A, Bausch & Lomb) and BioÀ nity® 
(comfilcon A, CooperVision) lenses. Briefly, the lenses 
were soaked in 100 ml of the test solutions, in triplicate, 
for four days. Confluent monolayers of L929 mouse 
À broblasts were then exposed to treated contact lenses 
for 24 hours and scored for reactivity according to USP 
Direct Contact Test criteria (Table 2). 21 Polypropylene 
pellets and latex rubber served as negative and positive 
controls, respectively.
Table 1 Solutions studied
Code Commercial name Composition Manufacturer
MPS-1 AQuify® Multi-Purpose 
 Solution
Sorbitol, Tromethamine, Pluronic F127, sodium phosphate 
  dihydrogen, Dexpant 5 (Despanthenol), EDTA, PHMB (0.0001 %)
Ciba Vision
MPS-2 ReNu® Multi-Purpose 
 Solution
Hydroxyalkylphosphonate, Poloxamine, PHMB (0.0001 %), 
  boric acid, EDTA, sodium borate, sodium chloride
Bausch & Lomb
MPS-3 OPTI-FREE® RepleniSH® 
 Multi-Purpose Solution
Sodium citrate, boric acid/borate, propylene glycol, 
  TearGlydeTM (Tetronic® 1304 + C-9 ED3A), polyquaternium-1 
(0.001 %), myristamidopropyl dimethylamine (0.0005 %)
Alcon Laboratories 
 Inc.
MPS-4 MeniCare Soft (Epica Cold) 
 Multi-Purpose Solution
Macrogolglycerol hydroxysterate 60, EDTA, tonicity agents, 
  propylene glycol, PHMB (0.0001 %)
Menicon
MPS-5 ReNu with MoistureLoc® 
 Multi-Purpose Solution
Boric acid/borate, Alexidine (0.00045 %), Hydranate, 
  polyquarternium-10, Poloxamine, Poloxamer 407
Bausch & Lomb
Perox Ciba Clear Care® 3 % H2O2, surfactant and platinum neutralizing disc Ciba Vision
NuMPS COMPLETE® RevitaLens Sodium citrate, boric acid/borate, polyquaternium-1 
  (0.0003 %), alexidine dihydrochloride (0.00016 %), EDTA, 
Tetronic 904
Abbott Medical 
 Optics Inc
Table 2 USP in vitro cytotoxicity direct contact test 
criteria
Grade Reactivity Description of the Reactive Zone
0 None No detectable zone around or under 
 specimen
1 Slight Some malformed or degenerated cells 
 under specimen
2 Mild Zone limited to area under specimen
3 Moderate Zone extends 0.5 to 1.0 cm beyond 
 specimen
4 Severe Zone extends greater than 1.0 cm 
 beyond specimen
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Clinical investigation
A three-month, double-masked, parallel group clinical 
trial comparing the safety and acceptability (comfort and 
lens cleanliness) of the NuMPS (test) to MPS-3 (control) 
was conducted with four types of silicone hydrogel 
contact lenses: Acuvue® Advance® (galyÀ lcon A, Vistakon), 
PureVision® (balafilcon A, Bausch & Lomb), O2Optix® 
(lotrafilcon B, CIBA Vision), Biofinity® (comfilcon A, 
CooperVision) and a FDA Group IV material (e.g., Acuvue® 2, 
[etaÀ lcon A Vistakon]). Subjects were enrolled in a 2:1 ratio 
(test vs. control) for each lens material. Of the 270 subjects 
enrolled, 177 were assigned to the test regimen and 93 to 
the control. In the test group the subjects used a “Rub and 
Rinse” regimen in their lens care whereas for the control a 
“No Rub but Rinse” regimen was used. Safety was primarily 
assessed through slit-lamp observations and the occurrence 
of adverse events (e.g. keratitis, hypersensitivity or visual 
acuity loss). 22 All slit lamp evaluation À ndings were graded 
on a 0 to 4 scale, where 0 = None, 1 = Trace, 2 = Mild, 
3 = Moderate, and 4 = Severe. Findings were categorized 
as: corneal edema, corneal neovascularization, corneal 
staining, bulbar hyperemia, palpebral conjunctiva and other 
À ndings. Acceptability was assessed via lens cleanliness (lens 
deposition as described below) and lens wearing comfort 
rated on a scale from 0-10 (0 = intolerable and 10 = cannot 
feel lens) compared to baseline assessments.
Protein and lipid deposit assessment of worn lenses
Lenses worn in a daily mode using either the test (NuMPS) 
or control multipurpose solution (MPS-3: see above 
section, Clinical investigation) were assessed at the 
end of a wear period (2 wks or 30 days, depending on 
lens type): n > 30/15 for test/control lenses for protein 
(left lens) or lipid (right lens) analysis for each lens type 
tested in the clinical investigation (see above section). 
All involved parties (including the analyst) were masked 
regarding control and test lenses. Protein analysis was by a 
modiÀ ed Lowry technique utilizing acetonitrile:water (1:1) 
containing 0.1 % triÁ uoroacetic acid to extract protein from 
lenses. 23 Lipid analysis involved extracting lipids from lenses 
with toluene:isopropanol (4:1), followed by deposition 
of the extracted lipids on a Teflon circular membrane 
(6 mm diameter) in a well of a 96-well plate (glass) by 
air evaporation. 24,25 Mid-infrared transmission analysis of 
the Teflon membrane with deposited lipids, based upon 
functional groups speciÀ c to lipid types, was done using a 
Nicolet Avatar-370 Fourier Transform Infrared Spectrometer. 
Glyceryl tristearate (99 %, Aldrich, USA) was used to prepare 
standards for the analysis.
Statistical analysis
Cochran-Mantel-Haenszel test was used to compare 
difference in overall corneal staining between the two 
regimens and Fisher’s exact test for adverse events. General 
Linear Model analysis was used to analyze acceptability 
measures for overall cleanliness and lens wearing comfort. 
Analysis of protein and lipid deposition on lenses was 
performed using Wilcoxon rank-sum test.
Results
Microbiology
The log10 reduction in bacterial and fungal viability 6 hours 
exposure time to the test solutions is shown in Table 3. 
With the exception of MPS-3, which gave a 2.3 log10 kill for 
S. aureus, all commercial MPS and Perox gave > 4.0 log10 
reduction in bacterial viability. A greater range in efÀ cacy 
was observed with the fungi. For C. albicans, MPS-1 and 
MPS-4 gave 1.0–1.1 log10 kill respectively and > 3.0 log10 for 
the other solutions, including Perox. For F. solani, a 
1.7-2.1 log10 reduction was obtained for MPS-4 and MPS-3, 
respectively, and > 3.0 log10 for all other commercial 
solutions. NuMPS showed > 4.0 and > 3.0 log10 reduction for 
all bacteria and fungi at 6 hours, respectively.
The results for the Acanthamoeba biocidal studies are 
shown in Table 4. All the solutions showed activity against 
trophozoites, ranging from 2.2–3.6 log10 kill after 6 hours. 
The results for the cysts were more variable and ranged 
from 0.1–2.4 log10 for MPS-3 and Perox, respectively, and 
> 3.0 log10 kill for the others.
With the regimen testing, the NuMPS gave < 10 cfu 
surviving bacteria and fungi on the lenses or in the soaking 
solution under No Rub but Rinse conditions and < 10 viable 
Table 3 Log10 reduction in bacterial and fungal viability after 6 hours exposure to test solutions
Log10 reduction in viability at 6 hours
Solution
Ps. aeruginosa 
(ATCC 9028)
S. marcescens 
(ATCC 13381)
S. aureus 
(ATCC 6539)
C. albicans 
(ATCC 10232)
F. solani 
(ATCC 36032)
AQuify® Multi-Purpose Solution (MPS-1) > 4.0 > 4.0 > 4.0 1.0 > 3.0
ReNu® Multi-Purpose Solution (MPS-2) > 4.0 > 4.0 > 4.0 3.5 > 3.0
OPTI-FREE® RepleniSH® Multi-Purpose Solution
 (MPS-3) > 4.0 > 4.0  2.3 3.3  2.1
MeniCare™ Soft (Epica Cold) Multi-Purpose 
 Solution (MPS-4) > 4.0 > 4.0 > 4.0 1.1
 
1.7
ReNu MoistureLoc Multi-Purpose Solution (MPS-5) > 4.0 > 4.0 > 4.0 3.1  3.0
Ciba Clear Care® (Perox) > 4.0 > 4.0 > 4.0 3.1 > 3.0
COMPLETE® RevitaLens (NuMPS) > 4.0 > 4.0 > 4.0 3.7 > 3.0
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Acanthanmoeba trophozoites or cysts when Rub and Rinse 
was used.
No evidence for trophozoite encystment (0 %-5 %) was 
observed during 24 hr incubation in any of the test or NuMPS 
solutions. The control encystment solution of Complete® 
MoisturePlus® MPS gave 30 % encystment.
The efficacy of test solutions against F. solani and A. 
castellanii trophozoites after evaporation to 2× and 4× 
concentration and a 6 hr disinfection time is shown in Table 5. 
For F. solani, MPS-5 and MPS-3 lost 85 %-98 % and 70 %-85 % of 
activity at 2× and 4× concentration, respectively. No loss in 
efÀ cacy on concentration was found with MPS-2 or NuMPS. For 
A. castellanii trophozoites, MPS-5 showed a 13 %-51 % reduction 
in efÀ cacy and MPS-3 a 38 %-9 % loss at 2× concentration and 
4×, respectively. MPS-2 gave a 14 % loss in activity at 2× 
concentration and 0 % at 4×. No loss in trophozoite efÀ cacy 
on concentration was found with NuMPS.
Cytotoxicity
In vitro cytotoxicity results are described in Table 6. Here 
NuMPS showed grade 1 (slight) with PureVision® and grade 2 
(mild) with Acuvue Advance® and O2Optix® lenses, compared 
to MPS-3 which exhibited a grade 3 (moderate) for these 
SiHy lenses. Both solutions scored a grade 2 for Soflens® 
38 lenses and grade 3 for BioÀ nity® lenses.
Table 4 Log10 reduction in A. castellanii trophozoite and cyst viability after 6 hours exposure to test solutions
Log10 reduction in A. castellanii trophozoite 
and cyst viability (6 hr)
Solution Trophozoites Cysts
AQuify® Multi-Purpose Solution (MPS-1) 2.2 3.3
ReNu® Multi-Purpose Solution (MPS-2) 2.8 3.2
OPTI-FREE® RepleniSH® Multi-Purpose Solution (MPS-3) 2.6 0.1
MeniCare™ Soft (Epica Cold) Multi-Purpose Solution (MPS-4) 3.2 3.1
ReNu MoistureLoc Multi-Purpose Solution (MPS-5) 3.6 3.4
Ciba Clear Care® (Perox) 3.4 2.4
COMPLETE® RevitaLens (NuMPS) 3.6 3.5
Table 6 In vitro cytotoxicity scores for NuMPS and MPS-3 according to USP direct contact test criteria
Cytotoxicity scores
 PureVision® Acuvue® Advance® O2Optix® SoÁ ens®38 BioÀ nity®
NuMPS 1 2 2 2 3
MPS-3 3 3 3 2 3
Latex rubber (positive control) 4 4 4 4 4
Polypropylene pellets (negative control) 0 0 0 0 0
Table 5 Effect of evaporation on F. solani and A. castellanii trophozoite disinfection
F. solani (ATCC 36031) A. castellanii (ATCC 50370)
 Conc Log10 kill (6 hr) % loss in efÀ cacy Log10 kill (6 hr) % loss in efÀ cacy
ReNu MoistureLoc Multi-Purpose Solution 1× 4.0 0 3.9  0
 (MPS-5) 2× 0.6 85 3.4 13
4× 0.1 98 1.9 51
ReNu® Multi-Purpose Solution (MPS-2) 1× 4.0 0 3.5  0
2× 4.0 0 3.0 14
4× 4.0 0 3.5  0
OPTI-FREE® RepleniSH® Multi-Purpose 1× 4 0 3.4  0
 Solution (MPS-3) 2× 1.2 70 2.1 38
4× 0.6 85 3.1  9
COMPLETE® RevitaLens (NuMPS) 1× 4.0 0 3.9  0
2× 4.0 0 3.9  0
4x 4.0 0 3.9  0
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Clinical investigation
The overall results indicated no significant difference 
in corneal staining between the two regimens. Corneal 
staining incidence at Day 90 was 18 % trace and 2.9 % 
mild with NuMPS; and 11.9 % trace, 3.6 % mild, and 1.2 % 
moderate with MPS-3 (p > 0.05). However, the incidence 
of adverse events in control subjects was significantly 
greater than the test subjects with 11.8 % (11/93) versus 
2.8 % (5/177), respectively (p < 0.05). These adverse events 
were not speciÀ c to any one lens type, but were more often 
inÁ ammatory (keratitis, conjunctivitis) or hypersensitivity 
responses (solution sensitivity, redness, tearing, etc.) with 
no cases of conÀ rmed microbial infection. With regard to 
acceptability measures, there was no signiÀ cant difference 
between the two regimens among all lenses tested in terms 
of overall cleanliness and lens wearing comfort, with lens 
wearing comfort mean ratings in the test and control groups 
of 8.7 and 8.6, respectively (p > 0.05).
Protein and lipid deposit assessment of worn lenses
The conventional etaÀ lcon A (Acuvue 2®) worn lenses were 
found to contain much higher levels of protein than any of 
the four silicone hydrogel types, with average protein levels 
of 50-60 mg/mg of dry lens material (Table 7). Although the 
average protein for this lens type (FDA Group IV) slightly 
favored the control solution (MPS-3), it was not statistically 
signiÀ cant (p = 0.10). All four silicone hydrogel types showed 
an average of less than 1 mg protein per mg of dry lens 
material for lenses used with either the control (MPS-3) or 
test solution (NuMPS). No statistically signiÀ cant difference 
was found between the solutions regarding protein 
deposition on three of the silicone hydrogel lens types 
(p = 0.70-0.97). However, lotrafilcon B lenses (O2Optix®) 
exhibited a signiÀ cantly lower level of protein deposition 
with NuMPS (0.04 mg/mg of lens) compared to the control 
MPS-3 (0.12 mg/mg, p = 0.01).
As shown in Tables 8-9, lipid levels were signiÀ cantly higher 
for all worn silicone hydrogel lenses (1-5 mg/mg of dry lens 
material, depending on lens type) than for the conventional 
etaÀ lcon A (Acuvue 2®) lens type (0.4 mg/mg of lens). Of 
the silicone hydrogel lenses, galyÀ lcon A (Acuvue Advance®) 
showed the highest total lipid deposition (~4.0 mg/mg) and 
lotraÀ lcon B (O2Optix®) exhibited the lowest (~1.0 mg/mg). 
There were no statistically significant differences in the 
amount of lipid deposition between the test and control 
solutions, although balafilcon A lenses (PureVision®) 
deposited less ester-type lipids (such as aliphatic glyceride 
esters) with NuMPS than MPS-3 with data tending toward 
significance (p = 0.06). Overall, the average amount of 
total lipid deposition for all lenses was identical for the two 
products and averaged 2.2 mg of lipid per mg of lens.
Discussion
Microbial keratitis is a rare but significant risk among 
contact lens wearers and studies have indicated that the risk 
of infection is around 2 cases per 10,000 soft contact lens 
wearers per year, rising to 19.5-25.4 cases per 10,000 for 
conventional hydrogel and silicone hydrogel lenses, 
Table 8 Ester-type lipid deposition levels (mg/mg of dry lens material) after continuous daily use of particular lens types 
(for the maximum recommended time) of NuMPS relative to MPS-3 as assessed by ex-vivo analysis of human worn lenses
Contact Lens Type GalyÀ lcon A 
(Acuvue® Advance®)
BalaÀ lcon A 
(PureVision®)
LotraÀ lcon B 
(O2Optix®)
EtaÀ lcon A 
(Acuvue® 2)
ComÀ lcon A 
(BioÀ nity®)
Statistical Parameter NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3
N 32 17 31 15 31 16 31 16 37 19
Mean 5.5 4.4 3.2 5.1 0.88 1.10 0.22 0.07 0.75 0.55
SD 4.7 2.9 1.6 5.3 0.67 0.68 0.63 0.16 0.57 0.31
P-value 0.39 0.06 0.29 0.32 0.17
Table 7 Protein deposition levels (mg/mg of dry lens material) after continuous daily use (for the recommended maximum 
time) of NuMPS relative to MPS 3 as assessed by ex-vivo analysis of human worn lenses
Contact Lens Type GalyÀ lcon A 
(Acuvue® Advance®)
BalaÀ lcon A 
(PureVision®)
LotraÀ lcon B 
(O2Optix®)
EtaÀ lcon A 
(Acuvue® 2)
ComÀ lcon A 
(BioÀ nity®)
Statistical Parameter NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3
N 32 17 30 15 31 15 31 16 37 19
Mean 0.10 0.10 0.31 0.30 0.04 0.12 59.3 49.9 0.12  2.60*
SD 0.08 0.12 0.14 0.18 0.06 0.11 18.7 14.2 0.13 10.78*
Median 0.10 0.08 0.29 0.26 0.04 0.07 62.42 55.8 0.09  0.08
P-value 0.970 0.800 0.012 0.099 0.697
*The high SD for this cell was caused by one outlier exhibiting very high protein deposition; thus the median is a better gauge in this 
particular case.
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respectively, if worn overnight. 3 In Acanthamoeba keratitis 
almost 90 % of cases occur in contact lens wearers and can 
result in permanent blindness. The reported incidence of 
Acanthamoeba keratitis varies from 1-2 cases per million 
in the USA or 17-20 in the UK. 4,26 Accordingly, contact lens 
care solutions have a fundamental role in the destruction 
or inhibition of potentially pathogenic microbes and the 
prevention of microbial keratitis.
The antimicrobial efficacy of contact care solutions is 
typically assessed according to ISO 14729 regulations. 10 
Using the same bacterial and fungal species and strains as 
this study, the regulations state that a contact lens solution 
should display appropriate efficacy by either the Primary 
Stand Alone (biocidal) or Secondary Regimen tests. In the 
former, the solution should produce a 3 log10 reduction 
in bacteria and a 1 log10 for the fungi without a regimen. 
If this is not possible, then the solution may be eligible for 
Regimen QualiÀ cation providing it was able to demonstrate, 
at the manufacturer’s recommended soaking time, stasis for 
the fungi and an average of 5 log10 reduction in the three 
bacteria, with at least 1 log10 occurring for each bacterium. 10 
If this condition is met the solution is eligible for the 
Secondary Regimen assessment. Here, the test evaluated 
the antimicrobial efÀ cacy of the entire lens care regimen 
according to the manufacturer’s instructions for use (e.g. 
rubbing, rinsing, soaking). Contact lenses are inoculated with 
at least 5 log10 of organism and following the Regimen an 
average of not more than 10 viable organisms should remain 
on the lens or the soaking solution. 10 To date, no requirement 
has been established for testing against Acanthamoeba. 10
With the exception of MPS-3, which produced only a 
2.3 log10 with S. aureus (ATCC 6538), all the commercial 
solutions and NuMPS studied here met the ISO 14729 Primary 
Stand Alone (biocidal) criteria for bacterial and fungal 
efficacy at 6 hr contact time. Failure to pass biocidal 
criteria does not preclude a MPS from the market place 
providing it passes the secondary regimen requirement. 10 
In addition, all of the solutions tested including the NuMPS 
showed biocidal efÀ cacy against A. castellanii trophozoites 
and, with the exception of MPS-3, the cysts. The NuMPS 
also met the ISO 14729 Secondary Regimen test for bacteria 
and fungi using a No Rub but Rinse procedure. For the 
Acanthamoeba only a Rub and Rinse regimen was used as 
previous studies have shown that the organism adheres 
with great afÀ nity to silicone hydrogel lenses. 5,27 As such, 
only the inclusion of a rub step can ensure satisfactory 
removal of trophozoites or cysts, as was demonstrated 
here. 5 Therefore, it is recommended that a rubbing step 
always be included in contact lens care regimen procedures 
to ensure effective removal of microorganisms and to aid 
lens cleaning.
MPS-5 (ReNu with MoistureLoc®) was withdrawn from the 
market in 2006 due to its association with a signiÀ cant rise 
in Fusarium keratitis cases. 12,28 The formulation, containing 
alexidine (0.00045 %), showed good activity against 
F. solani in biocidal assays. However, it was subsequently 
shown to have lost efficacy on film formation through 
desiccation in the lens case, most probably exacerbated by 
the presence of polymer PQ10 in the formulation. 14,29 The 
À ndings presented here extended this observation, showing 
that even on partial evaporation the solution lost 85-98 % 
of Fusarium activity. Loss in Acanthamoeba trophozoite 
efÀ cacy was also observed, with a 51 % reduction in activity 
at 4× concentration upon evaporation. This À nding is similar 
to that described previously with ReNu with MoistureLoc® 
in which a 70 %-80 % loss in Fusarium efÀ cacy was obtained 
with solutions formulated (rather than evaporated, as was 
done here) to 2× and 4× concentration. MPS-3 containing 
PQ-1 (0.001 %) and myristamidopropyl dimethylamine 
(0.0005 %) also showed a signiÀ cant loss in Fusarium efÀ cacy 
ranging from 70 %-85 % at 2× and 4× concentration. However, 
there are no reports associating MPS-3 with an increased 
risk of Fusarium keratitis, suggesting additional factors 
besides loss in biocidal efÀ cacy through evaporation may 
have been involved in the outbreak. In contrast, the NuMPS 
formulation, containing PQ-1 and alexidine showed no loss 
in Fusarium or Acanthamoeba efÀ cacy on evaporation to 
2 times and 4 times the concentration.
Another contact lens solution recall occurred in 2007 with 
the withdrawal of Complete® MoisturePlus® after it was 
linked to a number of Acanthamoeba keratitis cases. 13,15 It 
was subsequently shown that the solution induced signiÀ cant 
Acanthamoeba trophozoite encystment due, primarily, to 
the presence of propylene glycol in the formulation. 19,30 In 
this study, none of the solutions, including the NuMPS, were 
found to induce trophozoite encystment. The root cause 
for the association between Complete® MoisturePlus® and 
Acanthamoeba keratitis remains unclear and, despite the 
recall, the number of cases of infection related to the use 
of other contact lens solutions continues to be reported 
with increased frequency. 31
Although the antimicrobial adequacy of contact lens 
care solutions is currently directed by ISO 14729, recent 
events surrounding the recall of such products and the 
Table 9 Total lipid (ester and non-ester types) deposition levels (mg/mg of dry lens material) after continuous daily use 
of particular lens types (for the maximum recommended time) of NuMPS relative to MPS-3 as assessed by ex-vivo analysis of 
human worn lenses
Contact Lens Type GalyÀ lcon A 
(Acuvue® Advance®)
BalaÀ lcon A 
(PureVision®)
LotraÀ lcon B 
(O2Optix®)
EtaÀ lcon A 
(Acuvue® 2)
ComÀ lcon A 
(BioÀ nity®)
Statistical Parameter NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3 NuMPS MPS-3
N 32 17 31 15 31 16 31 16 37 19
Mean 4.2 3.5 2.4 3.0 0.88 1.21 0.37 0.43 2.8 2.5
SD 2.5 2.5 1.6 3.9 0.70 0.73 0.44 0.38 1.6 1.4
P-value 0.34 0.42 0.13 0.63 0.50
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À ndings of this study indicate that greater stringency is 
required. 10,12,19 Studies have also shown Fusarium strain 
variation in susceptibility to some MPS and, along with C. 
albicans, are signiÀ cantly more resistant to disinfection 
when present as biofilms compared to the planktonic 
state. 32,33 Based on these observations, it is recommended 
that the standard assessment of antimicrobial efÀ cacy of 
contact lens care solutions should be extended to include 
additional clinical strains of the ISO 14729 reference 
organisms along with Acanthamoeba for biocidal, regimen 
and encystment testing. Furthermore, the effect of 
evaporation on the loss of antimicrobial efÀ cacy should 
also be considered.
Clinical trials with NuMPS are ongoing and will be published 
in detail elsewhere. In the study described here, corneal 
staining change from baseline with NuMPS was found to be 
no greater than that with the control. Moreover, NuMPS 
was associated with appreciably fewer adverse events, 
none of which could be attributed to microbial keratitis. 
The trial also showed that NuMPS was comparable to the 
control solution with respect to lens cleanliness or wearing 
comfort.
Results from the present study showed NuMPS to have 
only slight to moderate cytotoxicity for all lens types 
studied and these À ndings were superior or equivalent to 
the control solution MPS-3. As the use of MPS-3 with some 
silicone hydrogel lenses has recently been associated with 
an increased incidence of corneal inÀ ltrative events, 34 the 
clinical implications of the cytotoxicity results from this 
study warrant further investigation to correlate in vitro 
biocompatibility to in vivo performance of the various 
MPS-CL combinations at the ocular surface. Previous in 
vitro studies have also reported that certain MPS may 
exert negative effects on cell viability and possibly other 
changes in corneal function including permeability, 
suggesting some cytotoxic inÁ uences from these MPS at the 
ocular surface. 35,36 Findings from these studies and others 
have demonstrated good correlation between cytotoxicity 
observed in human corneal epithelial cells (HCEC) compared 
to that in L929 cells. 37,38
Tear deposit assessment for total protein from worn 
lenses in the clinical trials showed greater deposition with 
the Group IV lenses than the silicone hydrogel lenses and 
that there were no statistically signiÀ cant difference in the 
levels between users of NuMPS and the control solution. Lipid 
levels were signiÀ cantly higher for all worn silicone hydrogel 
lenses compared to the group IV lenses. The observation of 
higher levels of protein deposition on conventional hydrogel 
compared with silicone hydrogel lenses is consistent with 
previous reports, as is the converse À nding that less lipid 
binds to silicone hydrogel lenses. 39-42
In conclusion, the NuMPS is a novel contact lens care 
solution based on the dual disinfection system of PQ-1 and 
alexidine. This solution was shown to provide antimicrobial 
activity against the pathogenic bacteria and fungi 
stipulated under ISO 14729 guidance as well as A. castellanii 
trophozoites and cysts. Unlike ReNu with MoistureLoc® MPS, 
which also contained alexidine, NuMPS maintained efÀ cacy 
on partial evaporation against Fusarium and Acanthamoeba. 
Furthermore, the NuMPS performed very well in both the in 
vitro cytotoxicity testing and clinical trials.
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